- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CHUGAI PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 18.05. | Roche-Tochter Chugai erhält Zulassungserweiterung für Krebsmittel Alecensa | 28 | cash | ||
| 24.04. | Chugai Q1 2026: Starkes Auslandsgeschäft und Pipeline-Fortschritte treiben Wachstum an | 10 | Investing.com Deutsch | ||
| 24.04. | Chugai Q1 2026 slides: overseas sales surge, pipeline advances | 19 | Investing.com | ||
| 24.04. | Chugai Pharmaceutical meldet starkes Umsatzwachstum für Q1 2026, Aktie gibt dennoch nach | 12 | Investing.com Deutsch | ||
| 24.04. | Chugai Pharmaceutical reports Q1 results | 2 | Seeking Alpha | ||
| 24.04. | Chugai Pharma Q1 Results Climb, Backs FY26 Outlook | 591 | AFX News | TOKYO (dpa-AFX) - Japan's Chugai Pharmaceutical Co., Ltd. (CHGCF.PK, 4519.T) reported Friday higher profit and revenues for its first quarter, and maintained fiscal 2026 outlookIn the first... ► Artikel lesen | |
| 20.04. | Chugai Pharmaceutical: Starke Verkaufsstarts bei Adipositas-Medikament treiben Aktie an | 2 | Investing.com Deutsch | ||
| 13.03. | Excillum and Chugai Technos announce partnership to introduce advanced battery inspection systems in Japan | 5 | Cision News | ||
| 30.01. | Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech | 6 | FierceBiotech | ||
| 29.01. | Chugai Pharmaceutical FY2025 slides: Record profits amid pipeline evolution | 3 | Investing.com | ||
| 29.01. | Chugai: Rekordgewinn im Geschäftsjahr 2025 - Pipeline-Anpassung verunsichert Anleger | 10 | Investing.com Deutsch | ||
| 29.01. | Chugai Pharmaceutical: Rekordgewinne im Geschäftsjahr 2025, doch Aktie gibt nach | 3 | Investing.com Deutsch | ||
| 29.01. | Chugai Pharmaceutical reports FY results | 2 | Seeking Alpha | ||
| 29.01. | Chugai Pharma FY25 Results Climb, Sees Growth In FY26 Core Profit, Revenues | 552 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) reported Thursday higher profit and revenues in fiscal 2025. The company further announced year-end dividends, and lower fiscal 2026... ► Artikel lesen | |
| 22.12.25 | Chugai Secures Regulatory Nod For Tecentriq In Thymic Carcinoma | 628 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Monday announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Tecentriq Intravenous Infusion for an... ► Artikel lesen | |
| 25.11.25 | Chugai Reports Positive Data From TEIEN Study Of Port Delivery System With Ranibizumab In NAMD & DME | 590 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Tuesday reported positive results from its phase I/II TEIEN study evaluating the Port Delivery System with Ranibizumab (PDS) in... ► Artikel lesen | |
| 25.11.25 | Chugai Pharmaceutical Teams With Biomy For Development Of AI-based Cancer Pathology Program | 657 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCY.PK), Tuesday announced a Memorandum of Understanding with Biomy, Inc., a provider of innovative services for pharmaceutical companies... ► Artikel lesen | |
| 24.10.25 | Chugai Pharmaceutical 9-month Net Income Rises | 607 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Chugai Pharmaceutical Co. reported, on a IFRS basis, nine month net income of 305.6 billion yen, up 3.3% from a year ago. Revenue was 911.6 billion yen,... ► Artikel lesen | |
| 17.10.25 | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | 750 | GlobeNewswire (Europe) | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen | |
| 19.06.25 | NEC Corporation: NEC and Chugai Pharmaceutical use AI to potentially enhance cancer treatment | 862 | JCN Newswire | - Identified the potential to reduce the time required to research and predict drug combinations by approximately 50% -TOKYO, June 18, 2025 - (JCN Newswire) - NEC Corporation (NEC; TSE: 6701), in collaboration... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TRULIEVE CANNABIS | 7,970 | -1,36 % | Trulieve Cannabis Corp.: Trulieve Reports Profitable First Quarter 2026 Results Bolstered by Margins and Cash Flow Generation | First quarter revenue of $287 million, with 59% gross margin
Positive net income of $2 million and Adjusted EBITDA of $100 million*
Rescheduling of medical... ► Artikel lesen | |
| WEST PHARMACEUTICAL SERVICES | 267,10 | -1,77 % | West Pharmaceutical Services, Inc.: West Appoints Michel Lagarde to be President and Chief Executive Officer | Experienced healthcare and life sciences executive to lead the Company's next phase of growth and innovation EXTON, Pa., June 1, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc.... ► Artikel lesen | |
| SHIONOGI | 15,695 | +1,65 % | Shionogi's COVID antiviral Xocova passes muster with FDA as post-exposure preventative | ||
| KALA BIO | 2,190 | -0,45 % | XFRA 27F: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKALA BIO INC. O.N.... ► Artikel lesen | |
| CHARLOTTES WEB | 0,434 | 0,00 % | Charlotte's Web Holdings, Inc.: Charlotte's Web Appoints Jeff Raborn to Board of Directors | Louisville, Colorado--(Newsfile Corp. - June 1, 2026) - Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) (Charlotte's Web or the Company), a botanical wellness innovation company and a... ► Artikel lesen | |
| BEXIMCO PHARMACEUTICALS | 0,410 | 0,00 % | Beximco Pharma: Gerichtsanhörung auf nach April verschoben | ||
| MIRUM PHARMACEUTICALS | 83,96 | +1,35 % | Mirum Pharmaceuticals, Inc.: Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 | - Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC) - Late-breaking Phase 2b AZURE-1... ► Artikel lesen | |
| LUYE PHARMA | 0,236 | 0,00 % | LUYE PHARMA (02186): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 26 JUNE 2026 | ||
| PERCHERON THERAPEUTICS | 0,004 | +14,29 % | PERCHERON THERAPEUTICS LIMITED: New HMBD-002 Data Presented at ASCO Annual Meeting | ||
| AYURCANN | 0,001 | 0,00 % | CSE Bulletin: Suspensions - Planet Green Metals Inc., Ayurcann Holdings Corp. | Le 9 mars/March 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101... ► Artikel lesen | |
| KALBE FARMA | 0,028 | -24,32 % | KLBF profit rises 13% in 2025, prepares IDR 500 billion buyback: Strong export lifts KLBF's net profit 13% to ... | ||
| AVANT BRANDS | 0,354 | -9,23 % | Avant Brands Inc.: Avant Brands Announces Voting Results from Its 2026 Annual General and Special Meeting of Shareholders | KELOWNA, BC / ACCESS Newswire / May 4, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU) ("Avant" or the "Company"), is pleased to announce the voting results from its annual general and special... ► Artikel lesen | |
| EVEREST MEDICINES | 3,360 | +1,20 % | Travere licenses kidney disease drug from Everest Medicines | ||
| KOBAYASHI PHARMACEUTICAL | 29,400 | -2,65 % | Kobayashi Pharmaceutical Co., Ltd. Profit Declines In Full Year | TOKYO (dpa-AFX) - Kobayashi Pharmaceutical Co., Ltd. (KBYPF) announced earnings for full year that Dropped, from last yearThe company's earnings came in at JPY3.656 billion, or JPY49.19 per... ► Artikel lesen | |
| BAYER | 33,350 | -5,07 % | Märkte am Morgen: Delivery Hero, MTU, Lufthansa, TUI, Airbus, Bayer, Space X | Nach der außergewöhnlichen Feiertagskonstellation - Pfingstmontag mit Handel in Deutschland, Memorial Day ohne Handel in den USA - tritt der DAX heute leicht auf die Bremse (-0,3 % erwartet). Gestern... ► Artikel lesen |
Das Unternehmen CHUGAI PHARMACEUTICAL CO LTD ADR kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 19,500 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHUGAI PHARMACEUTICAL CO LTD ADR finden Sie auf Wallstreet Online.